Immune Profiling for Cancer Immunotherapy Response

Recruiting now

Conditions studied: Cancer, Tumor, Solid, Hematologic Malignancy, Blood Cancer

In brief

In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.

Key facts

Study ID

NCT06116032

Run by

Dartmouth-Hitchcock Medical Center

People needed

1500

Starts

2022-10-03

Expected to finish

2029-01-01

Last updated by the study team

2025-12-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).
• Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).

You may not qualify if…

• Pregnant women/fetuses/neonates
• Prisoners
• Decision-impaired individuals

Where it is running

• Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.